Authors

Gina Z. D’Amato, MD, a professor of clinical medicine, assistant director of clinical research, medical director of the Nurse Practitioner Oncology Fellowship Program, and medical director of patient education at the Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami.

Latest:

Dr D’Amato on the Rationale for Studying Olaparib/Temozolomide in Leiomyosarcoma

Gina Z. D’Amato, MD, discusses the rationale for investigating olaparib plus temozolomide in previously treated advanced uterine leiomyosarcoma.

Gina Z. D'Amato, MD, Sylvester Comprehensive Cancer Center

Ginny Vachon, PhD

Latest:

RECORD-3 Molecular Analysis Characterizes Poor-Risk Patients With mRCC

To best treat patients with clear cell renal cell carcinoma, incorporating precision biomarkers into the current nomogram is essential.

Giorgio Scagliotti, MD, PhD

Latest:

Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

Giorgio Scagliotti, MD, PhD, University of Turin

Giorgio V. Scagliotti, MD, PhD

Latest:

Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

Giorgio Vittorio Scagliotti, MD, PhD

Latest:

Dr. Scagliotti on Preventive Measures to Reduce COVID-19 Risk in Oncology

Giorgio Vittorio Scagliotti, MD, PhD, discusses the precautionary measures implemented in clinical practice to protect patients with cancer from COVID-19.

Giovan Giuseppe Di Costanzo, MD

Latest:

Dr. Di Costanzo on the Effectiveness of Sorafenib in HCC

Giovan Giuseppe Di Costanzo, MD, Cardarelli Hospital, discusses a scoring system to predict the effectiveness of sorafenib (Nexavar) in hepatocellular carcinoma (HCC).

Giovanna Palatucci

Latest:

The Ratings Game

The rise of social networking websites that encourage patients to rate their physicians and discuss their experiences has some practitioners worried about the damage a malicious review could do to their practice.

Giovanni Grignani, MD

Latest:

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Girish Putcha, MD, PhD

Latest:

Dr. Putcha on the Utility of Blood-Based Assays in CRC

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Giselle Carnaby, PhD

Latest:

Patient Resistance to Swallowing Exercises After Multimodality Therapy

Giselle Carnaby, PhD, professor, ASHA fellow, Communication Sciences and Disorders, University of Central Florida, discusses rehabilitation of swallowing after multimodality therapy in patients with head and neck cancer, and why they may be resistant to it.

Giuseppe Banna, MD

Latest:

Dr. Banna on the Potential for CAR T-Cell Therapy in Lung Cancer

Giuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.

Giuseppe Curigliano, MD, PhD

Latest:

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Drs Park and Curigliano discuss the DESTINY-Breast06 trial of T-DXd in patients with HER2-low or -ultralow, HR–positive, metastatic breast cancer.

Glen Gejerman, MD, DABR, John Theurer Cancer Center

Glenn J. Lesser, MD

Latest:

Dr. Lesser on Armodafinil for Radiation-Induced Fatigue

Glenn J. Lesser, MD, Professor, Hematology & Oncology, Comprehensive Cancer Center, Wake Forest Baptist Health, discusses armodafinil for brain radiation-induced fatigue.

Glenn Liu, MD

Latest:

The Prostate Cancer Paradox Revisited

Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.

Gonzalo Sapisochin, MD

Latest:

Dr. Sapisochin on the Benefits of Living Donor Transplant in HCC

Gonzalo Sapisochin, MD, discusses the benefits of living donor liver transplantation in hepatocellular carcinoma.

Gopa Iyer, MD

Latest:

Dr. Iyer on Unmet Needs for Patients With TSC1/2-mutated Solid Tumors

Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.

Gordon B. Mills, MD, PhD

Latest:

Dr. Mills Gives Examples of Unexpected Drug Responses

Dr. Gordon Mills from MD Anderson Cancer Center Gives Examples of Unexpected Therapy Responses